After positive pre-clinical results, investigators at The Institute for Therapeutic Discovery have committed themselves to expanding their research of diabetes and diabetic neuropathy. Using a patented low-level antibody therapy (LLAT), it has been found that LLAT may reverse the disease, possibly eliminating the need for insulin. A key aspect of this leading-edge study will be the opening of a laboratory in Providence, RI, where the focus will be in the study of the mechanism of action for its novel therapeutic agent to treat these disorders.
